Joyce Abad
Quality Assurance Supervisor, Records
Quality Assurance Supervisor, Records
Quality Assurance Supervisor, Records
Vice President, Orthopedic Business Development
Vice President, Orthopedic Business Development
Dr. Al Rawashdeh has an interdisciplinary career focusing on the clinical translation of cell therapies and development of molecular imaging platforms. Prior to joining Ossium, he held a number of critical roles at Miltenyi Biotec, a global market-leader in cell processing, that enabled the creation of a successful CAR T cell therapy program. Dr. Al Rawashdeh developed industry-leading non-clinical development (NCD) and molecular imaging platforms and led the in vivo NCD packages of the CAR T cell therapy program, which in 4 years resulted in 4 CIT approvals in Germany, 1 IND pivotal trial FDA application, and 1 successful approval of an ‘orphan drug’ by the EMA. Dr. Al Rawashdeh developed a novel animal model that permitted the approval of the first CAR T cell clinical trial in Europe targeting melanoma.
On the research front, Dr. Al Rawashdeh spearheaded the initiation of an industry-academia consortium that successfully secured a major grant of $1.6 million from the EU European Funding for Regional Development initiative to develop novel CAR T cell therapies against solid tumors and cell tracking strategies, and led the project up to the time of his departure in 2021, when he joined Ossium.
As a postdoc at RWTH Aachen University, Germany’s top engineering university, Dr. Al Rawashdeh co-developed novel optical imaging technology that convinced MiLabs, a global leader in molecular imaging, to adopt the technology and build and commercialize a hybrid tomography system that generated over $10 million in sales to date. Furthermore, on the basis of his original research and project design where he recruited industry partners from Germany, Italy and the UK, he secured a $1 million grant from the European Union’s European Commission in the highly competitive multi-country BioPhotonics call.
Dr. Al Rawashdeh completed his BS from California State University, Fresno, and his MSc and Ph.D. from RWTH Aachen University.
Operational Excellence Lead
Operational Excellence Lead
Sterile Processing Technician
Sterile Processing Technician
Quality Control Supervisor, CLIA General Supervisor
Quality Control Supervisor, CLIA General Supervisor
Customer Success Specialist
Customer Success Specialist
Business Strategist
Business Strategist
Associate Director, Donation Compliance
Associate Director, Donation Compliance
Floor Supervisor, Sterile Processing
Floor Supervisor, Sterile Processing
Quality Assurance Associate Supervisor, Product Quality
Quality Assurance Associate Supervisor, Product Quality
Supervisor, Development; Lab Manager
Supervisor, Development; Lab Manager
CEO, Co-Founder & President
CEO, Co-Founder & President
As CEO, Co-Founder & President of Ossium Health, Kevin Caldwell has built Ossium from a small startup into a clinical stage bioengineering company. Kevin set the company’s mission to improve human health through bioengineering and designed its platform-based model for cellular therapeutics development. Kevin has led the company’s successful pursuit, negotiation, and execution of more than 50 business relationships, including 5 successful fundraisings and dozens of supply partnerships, clinical partnerships, and commercial contracts with biopharmaceutical companies.
Prior to founding Ossium, Kevin served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors. His projects ranged from due diligence of acquisition targets in the biotech startup ecosystem to restructuring distressed biopharma companies. Mr. Caldwell led more than 20 engagements with more than a dozen clients, leading teams that advised clients on revenue growth, go to market strategy, and organizational restructuring.
Before McKinsey, Kevin served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm’s global macro investments. Mr. Caldwell studied Physics and Economics at MIT before receiving his JD from Harvard Law School. Mr. Caldwell is a member of the Young President’s Organization (YPO), and a Fellow of the Leaders in Tech Program.
Manager, Facilities
Manager, Facilities
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Material Handler
Material Handler
National Trainer
National Trainer
Supervisor, Product Fulfillment
Supervisor, Product Fulfillment
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Quality Assurance Associate I, Operational Quality
Quality Assurance Associate I, Operational Quality
Manager, Supply Chain
Manager, Supply Chain
Sterile Processing Technician II
Sterile Processing Technician II
Vice President, People & Talent
Vice President, People & Talent
Ms. Gardner is a hands-on People leader with deep experience supporting high-growth startups across SaaS, cleantech, and fintech. Her focus is building scalable People and Talent infrastructure that emphasizes connection and engagement across multiple locations, teams, and levels.
Before joining Ossium, Ms. Gardner established the People team as employee #18 at Turntide Technologies, a cleantech electric motor startup with backing from Jeff Bezos, Bill Gates, and Robert Downey Jr. During her tenure, she cemented the People team as the connective tissue for a before-its-time hybrid model of 6 offices and 40% remote staff, and drove 555% headcount growth across the company. At Turntide she rolled out multiple people-focused initiatives including introducing OKRs, creating a recruiting playbook, founding a DEBI (Diversity, Equity, Belonging, & Inclusion) team, and building out the onboarding program Turntide 101. Ms. Gardner also spent 4 years in HR Consulting, working with startups across the nation to implement HR systems and best practices. Her team supported between 30-40 clients at any given time to onboard companies’ first hires, create a foundational HR base, and set the company up for future success with a focus on proactive consultative HR.
Prior to finding her calling in the People space, Ms. Gardner worked in guest operations at San Francisco’s two science museums: The California Academy of Sciences (where she presented public engagement shows underwater as a scuba diver) and the Exploratorium. Ms. Gardner received her BA in Feminist Studies from Stanford University, where she won a national championship as a member of the women’s water polo team and was named to the All-American team all four years. She also spent six months playing professional water polo overseas in Greece.
Medical Director
Medical Director
Director, Quality Control and Bone Marrow Fulfillment, CLIA Technical Supervisor
Director, Quality Control and Bone Marrow Fulfillment, CLIA Technical Supervisor
Supervisor, Clinical Production
Supervisor, Clinical Production
Sterile Processing Technician
Sterile Processing Technician
Associate Director, Regulatory Affairs
Associate Director, Regulatory Affairs
Principal Investigator, CLIA Technical Consultant
Principal Investigator, CLIA Technical Consultant
Environmental Technician
Environmental Technician
Floor Supervisor, Clinical Production & Safety Officer
Floor Supervisor, Clinical Production & Safety Officer
National Trainer II
National Trainer II
Supply Chain Buyer
Supply Chain Buyer
Clinical Production Specialist
Clinical Production Specialist
Quality Assurance Specialist, Donor Quality
Quality Assurance Specialist, Donor Quality
Senior Contracts Manager
Senior Contracts Manager
Development Associate II
Development Associate II
Research Associate III
Research Associate III
Vice President, Research
Vice President, Research
For the past 20 years, Dr. Johnstone has been actively involved in translating adult stem cell therapies into treatments for a host of diseases affecting the major organs of the body. In 2004, he co-authored one of the first studies demonstrating the potential for treating cardiovascular diseases with novel adult stem cells isolated from fat.
Since then, Dr. Johnstone has continued to develop and test new medical uses for adult stem cells as part of his own research as well as in collaboration with international academic centers and pharma / biotech firms.
Outside of the research setting, Dr. Johnstone co-founded NeuroFx, an early-stage biotech firm developing a novel therapy for neurological disorders. Dr. Johnstone led the R&D program at NeuroFx for two years, where he was directly responsible for preclinical and chemistry, manufacturing, and controls development activities. He continues to act as an advisor for NeuroFx. Additionally, Dr. Johnstone has formed two other biotech companies, Chemigen, which is developing a small molecule drug for treating Lou Gehrig’s disease, and EmphyMab Biotech (now Allinaire), which is developing biologics to treat serious lung diseases.
Before becoming an entrepreneur, Dr. Johnstone was an early employee at Sangamo Biosciences for 6 years, where he managed the preclinical development program for their lead gene therapy candidate for cardiovascular diseases, which is currently in Phase II clinical testing. Dr. Johnstone received his Ph.D. from the University of Maryland, College Park, and completed a postdoctoral fellowship at the University of California, Los Angeles.
Vice President, Finance
Vice President, Finance
Ed Jun is a thoughtful leader who empowers and inspires his teams to deliver exceptional performance in alignment with the company’s goals. He is a seasoned finance leader with a strong life sciences background who drives decision making based on the needs of the business and analytical acumen.
Before joining Ossium, Mr. Jun developed and led the Finance, Planning & Analysis team at Caribou Biosciences. As Caribou transitioned into a public company, he was instrumental in shaping new financial processes such as leading the budgeting, forecasting, board financials, and other financial analyses. Mr. Jun also led the FP&A function at Audentes Therapeutics, where he worked to integrate the company’s processes and financials into Astellas Pharmaceuticals. He also led the North America retail FP&A team at Activision Blizzard and spent 10 years at Pfizer in various commercial finance and FP&A roles. In 2016, Mr. Jun was recognized by the Asian American Business Development Center as one of the top 50 Outstanding Asian Americans in business. Mr. Jun received his BS in Mechanical Engineering and his MBA in Finance, both from Cornell University.
Senior Donor Services Specialist
Senior Donor Services Specialist
Quality Control Associate II
Quality Control Associate II
Director, Facilities
Director, Facilities
Quality Assurance Associate Supervisor, Donor Quality
Quality Assurance Associate Supervisor, Donor Quality
Cell Therapy Associate I, Clinical Production
Cell Therapy Associate I, Clinical Production
Quality Assurance Coordinator 3, Records
Quality Assurance Coordinator 3, Records
Senior Manager, Donor Services
Senior Manager, Donor Services
Cell Therapy Associate I, Clinical Production
Cell Therapy Associate I, Clinical Production
Cell Therapy Associate III, Clinical Production
Cell Therapy Associate III, Clinical Production
Quality Auditor
Quality Auditor
Quality Control Lead Medical Technologist, CLIA General Supervisor
Quality Control Lead Medical Technologist, CLIA General Supervisor
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Chief Medical Officer, Senior Vice President
Chief Medical Officer, Senior Vice President
Dr. Sagar Munjal has more than eighteen years of experience in drug development and product strategy. His expertise spans clinical development (phase I-IV), clinical operations, medical affairs, R&D, and global product launches. Dr. Munjal has worked in eight therapeutic areas and has brought four products to market. He has worked extensively with regulatory and government agencies, including the FDA, EMA, MHRA, ANVISA, and the DCGI. Dr. Munjal has drug development experience in small molecules, drug-device combination products, and biologics.
Dr. Munjal has managed global teams in the US, Europe, and India. He has worked with CROs of all sizes, investors, and scientific advisors. Dr. Munjal successfully negotiated a complex failed phase 3 study with the FDA to achieve product approval.
Before joining Ossium, Dr. Munjal worked at Dr. Reddy’s Laboratories Inc (USA), and was Chief Medical Officer at Promius Pharma LLC, a wholly owned subsidiary of Dr. Reddy’s. Previously, he worked at Johnson & Johnson, Altria, and in the clinic as an investigator. Dr. Munjal has published more than 30 manuscripts related to clinical studies, presented more than 60 abstracts at various scientific meetings, and was the recipient of the 2017 Harold G. Wolff award from the American Headache Society for key scientific contributions to the migraine field. Dr. Munjal received his MD from Karnataka University Dharwad and his MS in Clinical Research and Biostatistics from Virginia Commonwealth University.
Quality Assurance Specialist, Donor Quality
Quality Assurance Specialist, Donor Quality
Director, Clinical Production
Director, Clinical Production
Senior Manager, IT
Senior Manager, IT
Cell Therapy Associate I, Clinical Production
Cell Therapy Associate I, Clinical Production
Controller
Controller
Scientist 1
Scientist 1
Vice President, Technical Operations
Vice President, Technical Operations
Hans Nowak is a seasoned executive known for his leadership and expertise in manufacturing and supply chain operations, engineering, and business analytics. His strategic business experience, grounded in a robust technical foundation, has enabled him to optimize operational excellence and drive transformative growth across multiple complex, regulated industries.
Currently serving as the Vice President of Technical Operations at Ossium Health, Mr. Nowak leads day-to-day manufacturing, supply chain, and engineering operations, overseeing production output, product quality, and distribution. He also shapes our strategic operational vision to expand the product range, innovate for company growth, bolster manufacturing capabilities, and drive continuous competitive improvement while maintaining a safety-first and quality-always mindset.
Prior to Ossium, Mr. Nowak served as a Senior Engagement Manager at McKinsey & Company, where he led pharmaceutical and medical device companies through their most challenging operations and analytics problems. His projects ranged from heading the operational, quality, and digital transformations of manufacturing networks and sites to building product development strategies that significantly reduced development time, leading to rapid approvals of new molecular entities.
Before joining McKinsey, Mr. Nowak spent over a decade in engineering and operations leadership positions in industries ranging from nuclear engineering and defense to manufacturing operations and pharma. In these roles, he directed operations and maintenance of a reactor plant, consulted on manufacturing strategy, implemented cutting-edge automation and robotics solutions, led teams to formulate and aseptically fill medicine, and created advanced analytics tools to optimize operations and supply chains for Fortune 100 companies.
Mr. Nowak is a Navy submarine veteran and a graduate of the United States Naval Academy, where he received his BS in Applied Mathematics and BS in Quantitative Economics. He continued his education at MIT as a Leaders for Global Operations (LGO) Fellow and Siebel Scholar, graduating first in his class and receiving his MS in Mechanical Engineering from MIT’s School of Engineering and his MBA from the MIT Sloan School of Management. Mr. Nowak is certified in nuclear engineering, operations research, and business analytics, and he has shared his expertise by teaching courses at prestigious institutions such as IUPUI and MIT.
Senior Donation Compliance Specialist
Senior Donation Compliance Specialist
Senior Quality Assurance Associate
Senior Quality Assurance Associate
Quality Control Associate
Quality Control Associate
Associate Director, Technology
Associate Director, Technology
Director, Clinical Operations
Director, Clinical Operations
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Manager, Quality Assurance
Manager, Quality Assurance
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Quality Assurance Specialist, Process Improvement
Quality Assurance Specialist, Process Improvement
Senior Manager, Quality Systems
Senior Manager, Quality Systems
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Supervisor, Clinical Production
Supervisor, Clinical Production
Quality Assurance Specialist, Donor Quality
Quality Assurance Specialist, Donor Quality
Equipment Technician
Equipment Technician
Cell Therapy Associate II, Clinical Production
Cell Therapy Associate II, Clinical Production
Staff Accountant
Staff Accountant
Senior Database Engineer
Senior Database Engineer
Quality Assurance Specialist, Training
Quality Assurance Specialist, Training
Vice President, Donor Operations
Vice President, Donor Operations
General Counsel & Senior Vice President
General Counsel & Senior Vice President
Chip Walker-Wilson is the General Counsel & Senior Vice President, and he is responsible for overseeing Ossium Health’s legal and corporate governance functions.
Prior to joining Ossium Health, Mr. Walker-Wilson served as legal counsel at Cytokinetics, a clinical-stage biopharmaceutical company with development programs in the areas of cardiovascular and neurological diseases. At Cytokinetics, Mr. Walker-Wilson primarily supported the Research & Development Department, including the Clinical Operations, Non-Clinical Development, Research, Biometrics and Informatics groups. Prior to Cytokinetics, Mr. Walker-Wilson served as legal counsel at Dynavax Technologies Corporation, a biotechnology company with development programs in vaccines, cancer immunotherapies and autoimmune and inflammatory diseases. At Dynavax, Mr. Walker-Wilson provided support across the company, including the Research & Development, Technical Operations, Corporate Governance, Business Development, Information Technology, Regulatory, Quality, Human Resources and Medical Affairs groups. Prior to Dynavax, Mr. Walker-Wilson served as legal counsel at Abbott Laboratories. Mr. Walker-Wilson supported Abbott Diabetes Care, which is a medical device manufacturer that develops and sells blood glucose monitoring products. At Abbott, Mr. Walker-Wilson primarily worked with the Sales, Marketing, Strategic Partnership and Alliances, Business Development and Customer Service groups. Prior to Abbott, Mr. Walker-Wilson worked at the law firms of Orrick, Herrington & Sutcliffe and Sheppard, Mullin, Richter & Hampton, where his practice focused primarily on corporate and securities law and finance law.
Mr. Walker-Wilson received his B.A. in Legal Studies (with a minor in Rhetoric) from the University of California, Berkeley and his J.D. from the University of California, Berkeley School of Law.
Supervisor, Clinical Production
Supervisor, Clinical Production
Senior Floor Supervisor, Equipment
Senior Floor Supervisor, Equipment
People & Culture Generalist
People & Culture Generalist
Cell Therapy Associate III, Clinical Production
Cell Therapy Associate III, Clinical Production
Chief Science Officer, Co-Founder, EVP, CLIA Laboratory Director
Chief Science Officer, Co-Founder, EVP, CLIA Laboratory Director
Dr. Woods has devoted his career to advancing cell selection, culture and cryopreservation to facilitate mainstream clinical use of cellular therapies. Originally co-founding and leading General BioTechnology, LLC (GBT), a commercial cryobank, contract cell-manufacturing and R&D company, which he led for 15 years through successful acquisition by COOK Medical in 2012. During that time, he ran a continuously grant funded research program that created numerous successful technologies, including the first closed-system cryovial for cellular therapeutics, now marketed as CellSeal® by Sexton Biotechnologies, and the first mass produced human platelet lysate product, marketed as Stemulate®, both now used globally.
Following acquisition of GBT, Dr. Woods served as Senior VP of COOK Regentec and oversaw the scale up manufacturing of products in the US and Europe, and managed global projects involving multiple teams. Additionally, he served as an officer in Medistem, Inc., an early phase cell therapy company, where he developed isolation, manufacturing, and cryopreservation methods and prepared the CMC for their proprietary allogeneic Endometrial Regenerative Cell (ERC) technology IND and assisted in that company’s successful acquisition by Intrexon Corp.
Dr. Woods has a proven track record of developing new cell processing and banking technologies and translating them to the clinic. Over his career, he has been responsible for overseeing clinical laboratory operations as a board certified High Complexity Clinical Laboratory Director (HCLD), and in that capacity he ran the only FDA registered commercial sperm bank and the only umbilical cord blood bank in the state of Indiana, obtaining State Licensure, CLIA certification for testing, and American Association of Blood Banks (AABB) Accreditation.
Dr. Woods is a Fellow and Past President of the Society for Cryobiology and has published numerous peer reviewed manuscripts and book chapters and holds multiple patents in the field. Dr. Woods received his BA from Indiana University, his PhD from Purdue University, and he completed his postdoctoral research at the Indiana University School of Medicine.